In transthyretin amyloid, mitral regurgitation becomes dangerous well below guideline thresholds

Design

Multicentre international cohort with external validation, core-lab echocardiography

Population

1101 patients with newly diagnosed transthyretin amyloid cardiomyopathy

Primary outcome

All-cause mortality and first heart failure hospitalisation

Effect

Composite grade: 21% severe vs ≈12–13% by guidelines; HR for death 1.20 (1.07–1.36)

A multicentre cohort across eight centres in four countries studied 1101 patients with newly diagnosed transthyretin amyloid cardiomyopathy, split into a derivation group of 722 and an external validation group of 379. All had standardised echocardiography read blind in a core laboratory. Over a median of about 25 months, 28.5% died and 22.2% were admitted with heart failure.

Every measure of mitral regurgitation predicted both outcomes. Risk began to rise at an effective regurgitant orifice area of 0.10 cm², a regurgitant volume of 15 mL or a regurgitant fraction of 20%, and was high above 0.25 cm², 38 mL or 35%. A composite grading built on these thresholds classed 21% of patients as having severe regurgitation, against about 12–13% by guideline definitions, and discriminated outcomes better in both cohorts. After adjustment, only the composite grade stayed predictive for death (HR 1.20, 1.07–1.36) and heart failure admission (HR 1.21, 1.05–1.38).

The explanation is haemodynamic. A small, stiff ventricle with low stroke volume cannot generate the regurgitant volumes that define severe disease in a normal heart, so conventional grading reassures falsely. This is a prognostic study: it does not show that intervening on the valve at these lower thresholds helps, and no guideline has adopted them.

• In transthyretin amyloid, read 'moderate' mitral regurgitation on a standard report as potentially significant.
• Ask for quantitative measures — EROA, regurgitant volume and fraction — rather than a visual grade alone.
• A regurgitant volume of 15 mL or a fraction of 20% already marked higher risk in this cohort.
• Factor mitral regurgitation into prognosis discussions and follow-up intensity in amyloid patients.
• Transcatheter mitral repair decisions still rest on guideline criteria; these thresholds are not yet validated for intervention.

Why it matters

Conventional echo grading may be reassuring clinicians about valves that are already shaping outcome in amyloid hearts.

Don't overread it

This defines risk, not treatment: it does not show that repairing the valve at these thresholds improves survival.

The statistics, in plain English

A hazard ratio of 1.20 means about 20% higher risk of death per step up the composite grade after accounting for other factors; the interval excludes 1, so the association is unlikely to be chance. External validation in a separate cohort makes the thresholds more credible than a single derivation would.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.